Pacer Advisors, Inc. Supernus Pharmaceuticals, Inc. Transaction History
Pacer Advisors, Inc.
- $33.6 Billion
- Q3 2025
A detailed history of Pacer Advisors, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Pacer Advisors, Inc. holds 190,894 shares of SUPN stock, worth $9.5 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
190,894
Previous 288,231
33.77%
Holding current value
$9.5 Million
Previous $9.09 Million
0.41%
% of portfolio
0.03%
Previous 0.03%
Shares
24 transactions
Others Institutions Holding SUPN
# of Institutions
313Shares Held
61.5MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$517 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$309 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$239 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$150 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$137 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.66B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...